about
The emerging role of histone lysine demethylases in prostate cancerPharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaCYP2D6 polymorphisms and the impact on tamoxifen therapyTranscription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma.Hematologic toxicity of immunosuppressive treatment.Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study.The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer.Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenibA pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay.Pharmacogenetic determinants of anti-cancer drug activity and toxicity.Genetic variation: effect on prostate cancer.Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.Penetration of clofoctol into human lung.Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancerExpression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.Ceramide analogues in apoptosis: a new strategy for anticancer drug development.Cardiac toxicity of antineoplastic anthracyclines.Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.EPMA position paper in cancer: current overview and future perspectives.A benefit-risk assessment of basiliximab in renal transplantation.Biologic basis of ovarian metastasis of colorectal cancer.Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patientsPharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma.Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancersSuramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane.Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?Promoting predictive, preventive and personalised medicine: European event of global importanceEfficacy and safety of basiliximab in kidney transplantation.Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1.In vitro studies on gemcitabine combinations with other antiblastics.In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma.
P50
Q21245762-D5421E89-302D-413D-A68F-638153A0329FQ26781539-C3E983BC-612D-4942-A929-D3441E558DB2Q28303421-63DF68CC-3FC7-4239-9DF9-14A13EC30280Q33238550-3E29D9C6-7052-4DD2-9A09-CF9D8C6A7794Q33336057-CD40E30C-FE13-4246-A57F-79A66B4B0826Q33360584-E29A57FD-3E96-40BF-BA65-008ECB256986Q33378992-03F1362B-E3F9-4F5C-AF48-22A22197C21DQ33416977-303CE74E-42A6-4968-8BDB-8CF4C8E301EEQ33575825-F3B021CD-2D8E-484F-A8CB-01A920616E31Q33704464-18B1CB3C-EE68-4698-909C-C9A702B43C47Q33747098-F62B534C-D1BD-46C2-B53F-7E313723E916Q33914993-19D02AFF-B584-462A-B8ED-2EA075CDE14BQ34002264-DBB662B5-A274-4390-B674-CC31EF3B4C18Q34003771-813AD800-80AD-4AD6-A2C2-945D0CE734D7Q34036032-3E041DC8-3D90-4FB2-B1C3-2F092F218D90Q34177293-6D6A7EFF-5AFE-463F-8219-5C687B987C0BQ34322733-544F357D-F333-4E04-8684-4E8884FFF5F5Q34663656-2DC55DB9-3F5C-47DC-B075-0474173286E5Q34680467-C3FF1CF6-DD0D-4B40-8A4C-78C6B7014CD4Q34691268-D605360E-995A-4205-86F0-9E20B3293860Q34696189-39B2F727-8F13-4BF0-B5ED-0BD1458325CCQ34806780-68B4C265-71A8-47B2-A300-DDA4FBE46091Q34994625-F99A4DAC-0989-40D4-B1D2-1A9EEC20C33CQ35079308-ABA50036-F731-44DD-98F0-A59E11785C93Q35101035-25689844-DB2F-4C1A-9DA8-62B439D2BEF6Q35120829-B220FC08-9455-4366-9832-6A867B835215Q35532215-84935CA8-25EA-4580-8260-3B13A2BB25F4Q35626337-917F41C5-677C-4F60-A06D-1E9EC7DA78FBQ35693343-86213F5D-97B0-4559-8C28-C1D3D52FFA9CQ35803848-0093A0A8-59E0-48CB-AC4B-7908D5D004B5Q35808440-91F76FBF-26C7-476E-9299-83151623DE26Q35918752-901B9963-3E31-49EA-A951-AEC945E25F95Q35977856-DDC52178-C9B4-42BD-A75A-0A4654C5DE66Q36117656-30CBD22E-92CE-42D4-BA1B-0AF84CBE482AQ36117909-370CD121-E35F-445C-A0BD-B8DFBE81964DQ36150553-6BD1E792-8A57-4798-879F-5216DB6E613CQ36282739-511D9B25-95B9-4D8A-9245-FBBC1674FD5DQ36522723-DC0501B0-C498-49EF-B89A-7558F6EF3ED6Q36612195-A4374B87-3C47-4481-8FD8-ABE545E99CAFQ36614865-75BA44A1-919A-424B-87FA-F3C0C1102FB2
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
Danesi R
@ast
Danesi R
@es
Danesi R
@nl
Romano Danesi
@en
type
label
Danesi R
@ast
Danesi R
@es
Danesi R
@nl
Romano Danesi
@en
altLabel
Danesi R
@en
prefLabel
Danesi R
@ast
Danesi R
@es
Danesi R
@nl
Romano Danesi
@en
P31
P496
0000-0002-4414-8934